Table 4.

Compliant participant comparison in the comparator group only (at 6 week and 12 week).

	Week 6			Week 12
Scores	Active comparator (n = 80)	Placebo comparator (n = 100)	P -Value	Active comparator (n = 80)	Placebo comparator (n = 100)	P -Value
Measures of negative affect a
PSS score, median (IQR)	(n = 78)d	(n = 97)	0.082	(n = 73)	(n = 95)	0.017
	11 (7, 15)	13 (8, 17)		10 (5, 14)	13 (8, 17)
PHQ anxiety score, No. (%)	(n = 78)	(n = 97)	0.80	(n = 72)	(n = 93)	0.82
None	73 (93.6)	92 (94.9)		67 (93.1)	85 (91.4)
Mild	4 (5.1)	4 (4.1)		4 (5.6)	7 (7.5)
Moderate	1 (1.3)	1 (1.0)		1 (1.4)	1 (1.1)
PHQ depression score, No. (%)	(n = 78)	(n = 97)	0.34	(n = 72)	(n = 93)	1.0
None	72 (92.3)	93 (95.9)		70 (97.2)	90 (96.8)
Mild	6 (7.7)	4 (4.1)		2 (2.8)	3 (3.2)
Moderate	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)
Measures of positive affect b
Warwick-Edinburgh wellbeing scale score, median (IQR)	(n = 78)	(n = 97)	0.048	(n = 72)	(n = 93)	0.046
	55 (50, 61)	52 (45, 58)		56 (49, 61.5)	53 (46, 58)
DPES score, median (IQR)	(n = 78)	(n = 97)	0.029	(n = 72)	(n = 94)	0.32
	5.5 (4.5, 6)	5 (4.2, 5.8)		5.3 (4.5, 6)	5.2 (4.3, 6)
BRS score, median (IQR)	(n = 78)	(n = 97)	0.56	(n = 72)	(n = 94)	0.56
	2 (1.8, 2.2)	2 (1.8, 2.2)		2 (1.8, 2.2)	2 (2, 2.2)
Mindfulness scores c
MAAS score, median (IQR)	(n = 78)	(n = 97)	0.099	(n = 72)	(n = 94)	0.087
	4.8 (4, 5.4)	4.4 (3.6, 5.2)		5 (4, 5.5)	4.8 (3.8, 5.2)
COVID positive participants only
Post-Traumatic growth inventory score, median (IQR)	(n = 1)	(n = 1)	N/A	(n = 1)	(n = 2)	1.0
	56 (56, 56)	54 (54, 54)		48 (48, 48)	52 (28, 76)

^a Decline in scores suggests successful impact of meditation practices,

^b Increase in scores suggests successful impact of meditation practices,

^c increase in scores suggests successful impact of meditation practices,

^d(n = X) represents the number of patients with this score in the specific group at the specific time point.